Our Team

Julie has been part of the team at Scimega, since 2013.  Her passion for the business stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, her vision is to secure the company’s long term success by leveraging her in-depth industry expertise & business acumen.

Julie equates that success with setting a clear vision for the organization’s continued sense of purpose. She is responsible for developing successful business strategies & leveraging industry opportunities all of which support the common vision she shares with her team. Julie’s leadership & collaboration with the managing Board of Directors, esteemed colleagues with whom she has worked alongside for many years, ensure the business excellence upon which Scimega has built its reputation.

As CEO, Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Catherine currently serves as Scimega’s Vice President of Quality and Compliance. She has over 19 years of experience in complex clinical research and ICH GCP regulated and global environments. Dedicated to the successful conduct of oncology clinical trials in Canada Catherine ensures the effectiveness and continuous improvement of Scimega’s quality management system, aligned with the regulations. She is responsible for building a talented, qualified workforce at the company with continued enhanced performance aligned with Scimega’s mission and proactive quality culture. She also oversees the conduct of audits activities and GCP compliance consulting services at Scimega.

Catherine joined Scimega in 2006 as a Clinical Research Associate and has served several roles in the organisation in the clinical operations, human resources and quality & compliance departments. Prior to joining Scimega, Catherine worked mainly in medical research, notably in oncology clinical research, in both hospital and biopharmaceutical settings.

Catherine is a RQAP-GCP and lean certified professional. She holds a Master of Science in Neurosciences from University of Montreal and is a member of Scimega’s Board of Directors.

In 1997, Denise along with her business partner of 22 years, Andrée Marceau, launched Scimega, Canada’s first oncology CRO.  Denise’s unwavering vision was to position Scimega as a unique Canadian CRO fully dedicated to the clinical development of novel oncology compounds. In her role as President, Denise’s primary focus was on developing successful business strategies, leveraging opportunities and overseeing the company’s business development initiatives.  Today, Denise remains a partner in the business with an active interest in Scimega’s long term success.